Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based biotechnology company Siga Technologies has received a small business innovation research advanced technology Phase I grant from the National Institute of Allergy and Infectious Disease.
Subscribe to our email newsletter
National Institute of Allergy and Infectious Disease (NIAID) is part of the National Institutes of Health (NIH), and its grants are typically given to high-priority NIH programs.
The grant, totaling $963,000 over a two-year period, will help to fund lead optimization and animal efficacy trials for Siga’s dengue antiviral program. Successful outcomes from these activities could lead to a Phase II award in the future.
Dennis Hruby, chief scientific officer of Siga, said: “Funding from this grant will allow us to accelerate the Siga dengue program significantly and advance development of these drug candidates. Specifically, the grant will allow us to proceed with target identification and mechanism of action studies and to initiate animal efficacy studies.”